. By contrast, chemotherapy rarely induces CR in patients with metastatic carcinomas and sarcomas, multiple myeloma or chronic leukaemias [5] [6] [7] [8] [9] [10] . The introduction of effective targeted therapies has changed the response paradigm for some patients, such as those with chronic myeloid leukaemia (CML), epidermal growth factor receptor (EGFR)-mutated or ALK receptor tyrosine kinase (ALK)-rearranged lung adenocarcinoma, KIT proto-oncogene receptor tyrosine kinase (KIT)-mutated gastrointestinal stromal tumours and BRAF-mutated melanoma. Most patients with these diseases now achieve objective responses and, in some cases, even CR [11] [12] [13] [14] [15] [16] . A panoply of therapeutics that target other kinases, transcriptional modifiers, immune checkpoints and other cancer vulnerabilities is currently under preclinical and clinical investigation. Used as monotherapies and in combination, these agents are likely to usher in a new era in which patients Rationale for targeting MRD There are multiple conceptual advantages to treating patients with MRD-only disease rather than waiting for clinical relapse to initiate further therapy. First, the number of cancer cells is likely to be positively correlated with clonal complexity and thus with the likelihood of subclonal resistance to one or more therapeutics 19 (FIG. 1) .
Second, minimal numbers of malignant cells may be less effective at remodelling microenvironments, reprogramming infiltrating haematopoietic cells and inducing chemoprotective niches 20 . As a result, certain drugs may have greater efficacy against MRD than against the same cancer at the time of clinical relapse. Third, the ability of patients to tolerate drugs with substantial side effects may be better when only MRD is present compared with the time of fulminant relapse. Fourth, if cure requires the eradication of all tumour cells capable of driving relapse, there are likely fewer of these cells at the time of MRD. Cancer stem cells are less sensitive to many drugs than more differentiated tumour cells, but they are not completely resistant. Thus, it follows that cancer stem cells are enriched as a fraction of malignant cells within MRD, but their total number is likely reduced in MRD compared with the time of frank relapse 21 .
Evidence that treating MRD can increase the rates of cure. The strongest evidence that treatment of MRD can prevent relapse, which is a measurable surrogate for cure, comes from the experience of using adjuvant (and to some extent neo-adjuvant) therapy for epithelial tumours and sarcomas, which is fundamentally intended to eradicate MRD outside the surgical resection. Studies across multiple cancer types have confirmed that more patients achieve long-term disease-free survival with the combination of surgery and adjuvant (or neoadjuvant) therapy than with surgery alone [22] [23] [24] [25] [26] [27] [28] . Similarly, for haematological cancers such as acute leukaemias or aggressive lymphomas, a single cycle of intensive chemotherapy can induce CR, but virtually no patients are cured without additional therapy to eradicate MRD 29 . In patients with acute leukaemia, flow cytometry of blood or bone marrow can detect with advanced haematological and solid cancers achieve CR in both front-line and salvage settings.
CR, whether achieved by chemotherapy, targeted therapy, radiation, surgery or a combination, typically requires >99% (that is, >2-3 log 10 ) reduction in tumour burden 17, 18 . In a hypothetical patient with five metastatic lesions averaging 2 cm 3 each, this would equate to a reduction from approximately 10 10 tumour cells to <10 8 tumour cells (FIG. 1) . These remaining tumour cells have traditionally been called minimal residual disease (MRD). Not all MRD cells are likely to contribute to a clinical relapse, so the term MRD is somewhat nonspecific. Although a full discussion is beyond the scope of this Opinion, we introduce a potentially useful nomenclature to distinguish different types of residual matter in BOX 1.
For the sake of simplicity, we define MRD as follows: malignant cells that remain in a patient who achieves CR and that share phenotypic similarity (for example, histologic appearance and lineage markers) and genetic heritage (for example, truncal mutations and chromosomal rearrangements) with the original tumour cells. Residual cells that harbour somatic alterations and/or phenotypic alterations but are not fully malignant, such as those causing a dysplastic field effect, are not included in this definition of MRD.
aberrant immunophenotypic populations consistent with MRD at frequencies of ≤0.01% of cells 17, [30] [31] [32] [33] [34] . MRD detection with similar sensitivity is achievable by PCR or next-generation sequencing for gene fusions, patient-specific mutations or clonal rearrangements of immunoglobulin (in B cells) or T cell receptor (in T cells) genes 17, 30, 33, 34 . A positive test for MRD is not an absolute indicator of relapse, even upon completion of therapy, as the test may detect cells (or nucleic acids derived from those cells) that lack the ability to proliferate into a relapse
. Nonetheless, a positive test for MRD in these patients, regardless of method, has repeatedly been associated with inferior prognosis 33, [35] [36] [37] [38] [39] [40] [41] [42] [43] [44] [45] [46] .
Chemotherapy intensification based on MRD levels. Perhaps the most successful application of MRD-directed therapy is in children with acute lymphoblastic leukaemia (ALL), where tailoring consolidation therapy (that is, treatment after achieving CR) on the basis of MRD load is standard practice 47 . The presence or absence of MRD above defined thresholds directs relatively crude de-intensification (that is, lower doses) or intensification (that inform the rational selection of second-line or third-line therapy. Patients with CML who achieve optimal responses to first-line or second-line TKI therapy (defined as sustained, deep remissions of greater than 4-5 log 10 reductions in the BCR-ABL transcript according to the International Scale) may be candidates for drug cessation after multiple years of TKI therapy 50 . In recent trials, approximately one-half of patients who discontinued therapy under those circumstances remained in prolonged molecular remission [50] [51] [52] [53] [54] [55] . Figure 1 | Paradigms for management of MRD. The current approach is to treat patients until they achieve complete remission (CR). This could be through surgical resection, radiation, chemotherapy or a combination of these treatments. Patients are then typically observed until they relapse. Instead, minimal residual disease (MRD) could be sampled iteratively, tested for therapeutic susceptibility and treated with the agents identified as most effective by that test. Once a patient's MRD falls below the minimum detectable threshold (dashed line), treatment could be stopped, continued indefinitely or continued for a defined period with curative intent. Potential advantages and disadvantages of targeting MRD are listed and discussed further in the text. malignant cells. The reasons for this remain poorly understood, but one possibility is that CML stem cells are primarily quiescent and only intermittently enter the cell cycle 56, 57 . While quiescent, they fail to undergo oncogene withdrawal-induced apoptosis, although this apoptosis is readily induced by TKIs in more differentiated progeny 58 .
Complete eradication of the quiescent population may require that adequate inhibition of BCR-ABL kinase activity continues for long enough to allow each CML stem cell the chance to enter the cell cycle and thereby become susceptible to oncogene withdrawal-induced apoptosis. Populations of cells with stem cell-like properties exist in many types of cancer 59, 60 , suggesting that the requirement for extended therapy might be common.
The same concept of long-term therapeutic pressure is also established for ALL maintenance therapy with the thiopurines 6-mercaptopurine (6-MP) or 6-thioguanine (6-TG), which are given in combination with other low-dose chemotherapy agents for 2-3 years 61, 62 . Resistant clones that emerge late in this maintenance phase frequently harbour mutations in 5ʹ-nucleotidase, cytosolic II (NT5C2) that directly confer resistance to 6-MP and 6-TG 63, 64 . This mechanism of tumour cell-autonomous resistance suggests that thiopurines improve cure rates by directly killing the last leukaemia cells capable of driving relapse (that is, the MRD) rather than acting through non-tumour cell-autonomous mechanisms.
The second insight from the CML experience is that patients who inadequately respond to or relapse during first-line TKI treatment may still be curable with a second-line TKI that retains efficacy 53, 54 . Thus, the presence of resistance mutations within BCR-ABL does not eliminate the potential for CML to be cured, as long as therapeutics are available that overcome the resistance and can adequately inhibit BCR-ABL kinase activity for a long enough period of time.
This paradigm, in which a cancer retains equivalent curability in the first-line and second-line settings, may be more broadly applicable to other cancers treated with targeted therapies. However, it may not apply to cancers treated with clastogenic chemotherapies, as these agents induce genetic diversity and thus may promote the development of subclones that intrinsically lack responsiveness to other therapeutics (for example, by genetic loss of genes encoding apoptosis effectors 65 ).
cancers. For example, independent metastases from the same carcinoma can undergo divergent evolution that leads to differential therapeutic responses, and even primary solid tumours can have extensive geographic heterogeneity [66] [67] [68] . There is a widely held belief that haematological cancers may be less geographically heterogeneous than carcinomas, but this has not been systematically proved. The larger advantage for sampling MRD in patients with leukaemias and some lymphomas is that MRD cells can be isolated from the bone marrow. By contrast, the sites of MRD within a patient who underwent resection of his or her primary cancer are almost always unknown. Thus, two issues preclude MRD sampling for many patients with solid tumours: there is an inadequate signal:noise ratio for the detection of MRD by use of currently available imaging approaches, and biopsy of sites such as liver, bone, spleen and lung requires invasive sampling. The latter would have to be justified by improvements in outcome that come from therapeutic decisions based on analysis of the sampled material.
Assays that use circulating tumour cells (CTCs) and cell-free nucleic acids may be feasible for testing MRD in the future but are currently limited by the quantity of malignant material recovered by Approaches to characterize MRD Biological and functional challenges. An optimal assay performed at the time of CR would not only predict therapeutic response but also identify relevant heterogeneity that is present within the patient's MRD. It would utilize very small amounts of input material, generate easily interpretable data within a short period and require relatively little operator skill. Such an assay could be iteratively applied to assess MRD and to guide therapeutic selection (as in FIG. 1) . This would be a transformative clinical advance for patients with persistent MRD if selective targeting of MRD either forestalled or completely obviated clinical relapse.
A major concern with characterizing MRD is that sampling from a single site could result in misrepresentation of the true heterogeneity in situ. To some extent, heterogeneity within MRD can be addressed by iterative sampling, testing and therapeutic targeting. When the MRD is then reassessed, subclones (or cellular contents derived from them) that were not effectively targeted based on the previous assessment should be enriched within the sampled population.
There are theoretical challenges to bioassay-based targeting of solid tumour MRD that suggest the primary focus for this strategy should be on haematological In many contexts where the term 'minimal residual disease' (MRD) has been applied, each of the three words is contestable. We have generated several acronyms that more precisely define cells and other matter that are currently classified as MRD or used as de facto evidence of MRD.
Minimal relapsable cancer (M-REC).
Cancer cells that are fully transformed and capable of proliferating into a diagnosable relapse. Thus, these cells have both genetic and functional properties consistent with malignancy.
Minimal non-relapsable cancer (MN-REC). Cancer cells that are incapable of proliferating into a diagnosable relapse. These cells may have irreversibly differentiated beyond the ability to act as cancer stem cells, may have been damaged by chemotherapy, radiation or other treatment, or may otherwise lack the capacity to drive relapse (for example, owing to an inhospitable microenvironment).
Minimal residual precursors (MRPs). In contrast to M-REC, these are non-fully transformed cells that harbour genetic or other alterations that are also present within the tumour cells. Examples include clonal haematopoiesis in patients who achieve complete remission after leukaemia treatment 121 and dysplastic cells that persist after treatment for many types of localized carcinomas [122] [123] [124] [125] [126] [127] [128] [129] .
Minimal residual nucleic acids (MRNAs). Detectable nucleic acids that suggest, but do not prove, the existence of M-REC, MN-REC and/or MRPs. These may be detected within biopsy samples or from compartments such as the bloodstream, bone marrow, stool or cerebrospinal fluid. They may indicate the persistence of MRPs or could represent nucleic acids that arose from dead or excised tumour cells that have not been fully degraded. [83] [84] [85] , revealing intratumoural heterogeneity in both malignant and non-malignant populations 83, 86, 87 . However, these vast insights into tumour biology have not thus far been translated into clinically relevant approaches for selecting therapeutics for an individual patient 80 .
Minimal residual metabolites (MRMs

The evolution of functional assays.
Functional testing of therapeutic sensitivity of individual cancers initially followed similar paradigms that were overwhelmingly successful for determining antibiotic sensitivity in bacteria [88] [89] [90] . Tumour cells were plated in 2D culture ex vivo in the presence in some patients, such as those with EGFR-mutated lung cancer [75] [76] [77] [78] [79] . In tumours where a targeted agent is available and associated with genotype-specific activity (that is, the presence or absence of resistance mutations), sequencing of circulating tumour DNA could even be used to inform the selection of specific agents, as in CML. Unfortunately, nucleic acid-based biomarkers that predict sensitivity or resistance to cancer therapeutics are the exception rather than the rule 80 .
For the overwhelming majority of cytotoxic chemotherapies and many targeted agents, there are few if any genetic, transcriptional, proteomic, metabolomic or other biomarkers to predict the depth or duration of response. As a result, functional assays that directly measure phenotypic responses to single agents or therapeutic combinations are particularly attractive. We focus primarily on phenotypic assays, as they capture complex and multiparametric interactions to predict in vivo therapeutic efficacy. However, there are several transcriptional and proteomic assays that have the potential to define aspects of intratumoural biology and even link changes associated with drug exposure to clinical outcome. Among these, mass Nature Reviews | Cancer of potentially active therapeutics, and some marker of either survival or proliferation was measured. In contrast to antibiotic sensitivity testing, bulk assays for cancer therapeutic sensitivity were generally not useful for several reasons. First, extended culture of tumour cells is difficult, so comparisons between untreated and drug-treated cells are largely a 'race to death' . Second, available assays required relatively robust laboratory capabilities within a short distance from the patient bedside, as extended transport further compromises tumour cell survival. Third, the prolonged culture necessary to readout survival or growth resulted in notable selection for cells with characteristics that favour in vitro survival. Finally, and importantly, these assays were primarily conducted in an era when cancer therapeutics were not very active against most solid tumours, so the chances of identifying a highly effective therapy (including combinations) was a priori low. There are several strategies for overcoming issues related to selection in 2D culture. Multiple groups have established either organoids from individual patient tumours or patient-derived tumour xenografts (PDXs). Both strategies may capture relevant interactions that mimic the in situ microenvironment but also require extended propagation that allows for clonal selection and a temporal gap between the biopsy and the readout for drug efficacy [91] [92] [93] [94] . An alternative approach is to either eliminate or reduce the need for ex vivo propagation through the use of a rapid readout of single-cell treatment response. Several assays have been reported that can measure proteomic, transcriptional, functional or other readouts of drug response within cancer cells and could be tested on MRD. A non-exhaustive sampling is included in TABLE 1.
One promising approach for assaying the effects of multiple drugs on a single tumour specimen ex vivo is dynamic BH3 profiling (DBP). This assay quantifies treatmentinduced changes in net pro-apoptotic signalling within mitochondria 95 . In DBP, patient tumour cells are exposed to drugs for 16-24 hours ex vivo, permeabilized and exposed to pro-apoptotic, BH3-domaincontaining peptides. The frequency of cells that undergo mitochondrial outer membrane permeabilization is measured to assess the extent to which tumour cells are primed for apoptosis. The difference between priming in the presence and absence of exposure to a therapy within the bulk tumour population is used to predict the effects of therapeutics when exposed to samples ex vivo 100 . Flow cytometry-based assays offer the added benefit that 10 5 -10 6 cells can be easily analysed from a single sample, which allows for the interrogation of MRD present at frequencies less than 1 in 10,000 cells.
Together with colleagues at the Massachusetts Institute of Technology and the Dana-Farber Cancer Institute, we have been testing whether a measurement device for single cells known as the suspended microchannel resonator (SMR) can be applied to assess functional drug response in single cancer cells (FIG. 3) . When an object denser than media passes through the SMR, the net increase in mass (that is, the buoyant mass of the object) lowers the resonant frequency. To measure the mass accumulation rate (MAR) of a cell, an array of SMRs are microfluidically connected whether the therapy will be effective in the patient 96 . DBP has been used to accurately predict the response of CML to imatinib therapy by use of bone marrow samples, the response of single-cell suspensions from ovarian cancer biopsies to carboplatin therapy, the response of ALL PDXs to E3 ubiquitin-protein ligase MDM2 inhibition and in other settings 95, 97, 98 . Although many drugs have yet to be tested using DBP, the assay is likely to be amenable to a wide range of targeted therapies that act through the intrinsic apoptotic pathway in tumour cells. Like 2D culture, organoids and PDXs, DBP queries the treatment response of tumour cells in bulk rather than in individual cells, although advances in flow cytometry-based DBP may allow for its application to single cells 99 . Other approaches that utilize flow cytometry could also be applied to assay The formats listed in the table are an incomplete list of example technologies. DBP, dynamic BH3 profiling; MRD, minimal residue disease; RNA-seq, RNA sequencing; SMR, suspended microchannel resonator. *Some assays could be used across the different categories (for example, aptamers could be used in microwell plates to detect RNA transcript abundance rather than proteins). Additional biophysical assays (for example, measuring deformability) have not been explored in MRD but may be feasible. ‡ Some assays, such as microscopy and SMR, are likely to require pre-enrichment of tumour cells from MRD before employing the assay. § Some assays, such as flow cytometry and mass cytometry, will vary in the need for pre-enrichment based on the frequency of MRD in the starting population. While these assays could likely characterize MRD at frequencies of 1 in 1,000 to 1 in 10,000 cells, further technical innovation will be necessary for even lower frequencies.
in series, with delay channels in between each cantilever. Passage through the delay channels provides the cell with time to gain or lose biomass before the next cantilever. After a cell exits a cantilever, other cells are free to enter it and be weighed. Over 100 cells per hour can pass through the array in a queue, each being measured with a precision near 0.01% of the cell's weight 101, 102 . MAR is a measurement of cell growth that does not require proliferation. Thus, like DBP, the MAR assay can rapidly assess drug response whether that drug is applied in situ or ex vivo 103 . and resistant cells to be interrogated by live-cell downstream assays such as scRNA-seq or DBP (FIG. 3b) . Because these properties are measured for each single cell, clonal architectures based on therapeutic response can ultimately be established across each tumour sample by incorporating molecular and functional measurements from large numbers of cells. In settings of deep treatment response, pretreatment and MRD samples can be compared to define the effects of therapy on clonal architecture. We envision that these data could then be incorporated into mathematical models to design and optimize therapeutic approaches that address the heterogeneity within individual tumours that results in treatment failure.
There are multiple additional methods for measuring biophysical properties of single cells with high throughput that have not yet been fully exploited for assessing drug responses. For example, microscopy can quantify cell size and morphology 105 , and several different microfluidic approaches have been used to interrogate mechanical properties of single cells [106] [107] [108] [109] . Label-independent techniques that exploit differences in the size, shape or rigidity of malignant versus non-malignant cells also exist but have not yet been fully exploited for identifying MRD cells.
Tumour cell enrichment and assay sensitivity. For most platforms listed in TABLE 1, tumour cells must be pre-enriched before assaying drug response, as the throughput is insufficient to capture an adequate number of malignant cells within a sample containing primarily non-malignant cells. Pre-enrichment typically involves targeting cell surface proteins by use of antibodies conjugated to magnetic beads or fluorescent molecules followed by either flow-associated cell sorting or positive selection with magnetic beads [110] [111] [112] [113] . Even with advances in tumour cell enrichment, there is a minimum threshold for involvement of MRD below which an assay is simply not feasible. For example, a recent study on MRD in multiple myeloma used next-generation flow cytometry on bone marrow to identify approximately two MRD cells per million 114 . Although identification of MRD at this frequency is now possible, sorting and then drug testing these cells are unlikely to be possible. However, testing frequencies of MRD between 1 in 10,000 and 1 in 1,000 cells should be feasible based on
We have demonstrated that the MAR assay can define the drug sensitivity or resistance of glioblastoma and B cell ALL cells to targeted agents 103 . For multiple myeloma, we have recently demonstrated that the MAR assay accurately and rapidly defines therapeutic susceptibility in human multiple myeloma cell lines. In a study of six patients who responded to therapy that included the proteasome inhibitor bortezomib and three who did not, MAR correctly predicted response with 100% accuracy 104 . Importantly, the MAR assay is nondestructive, which allows both sensitive . Imatinib was added to cultured BCR-ABL-expressing BaF3 cells at T = 0, and the culture was continuously sampled using a serial SMR 101 for 8 hours. Each cell takes ~20 minutes to pass through the 12 serial SMRs (sSMRs) (black = first SMR, red = last SMR), and the slope of the resulting growth trajectory is the mass accumulation rate (MAR). Initially, the trajectories have a positive slope, but after 6 hours, the slope approaches zero. Although the imatinib-treated cells remained viable for >36 hours before measurable induction of apoptosis, the MAR decreases in just a few hours. b | Functional properties, such as MAR, that are rapidly affected by effective therapeutics and precede longer-term phenotypes (for example, loss of viability) can be linked to molecular properties by isolating individual cells in wells and performing downstream assays. In this example, MAR is used to identify responding (sensitive) and nonresponding (resistant) cells before single-cell RNA sequencing (scRNA-seq) in order to search for programmes and cell states associated with resistance. Part a courtesy of N. Cermak. [116] [117] [118] .
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The future of MRD-guided therapy It remains to be determined whether applying any approach to MRD samples can lead to the selection of treatments that extend the duration of CR over current empirical approaches. However, it seems intuitive that a greater appreciation of heterogeneity in the response of individual MRD cells to a therapy (including combinations) can inform therapeutic selection, provided therapies exist that are capable of overcoming the resistance. It also seems intuitive that patients will accept more invasive sampling, even multiple biopsies, at the time of MRD if that sampling has been proved to inform therapeutic selection and confer meaningful benefit.
As newer and more effective agents are introduced for patients with cancer, we can now envision preventing disease relapse through the rational targeting of MRD. The achievement of that ambitious goal will require carefully designed trials in selected settings that apply novel approaches for sampling and testing live MRD cells. One can envision two paradigms for targeting MRD. In the first, patients would be treated until MRD is no longer detectable and then given drug-free holidays until MRD relapses (as in FIG. 1) . At that time, MRD would be assessed for therapeutic sensitivity and the appropriate treatment initiated (or re-initiated). This is a form of preemptive therapy similar to the suppression of viral reactivation among immunocompromised patients 119 . In the second paradigm, treatment would continue either indefinitely (akin to secondary prophylaxis of infections) or with curative intent. The ability to cure a tumour will depend on several factors, most notably the efficacy and lack of cross-resistance among therapeutics for that disease.
Clinical settings ripe for initial trials include haematological neoplasms in which patients commonly achieve CR to initial therapy but are prone to relapse from MRD after completion of therapy, such as acute and chronic leukaemias, lymphomas and multiple myeloma. Multiple drugs have single-agent activity in these patients, but few biomarkers are available to guide drug selection.
In a trial that tests functional assessment of MRD, patients could be randomized to receive either the treatment predicted to be optimal based on MRD testing or the treating physician's choice of therapy. Upon treatment failure (either upfront failure or failure after a period of response), MRD cells would again be isolated from patients. The cells would be tested using the functional assay, and the results would guide therapeutic selection (if randomized to that arm) or kept confidential (if randomized to physician's choice). This would continue iteratively until the patient was either cured or underwent a clinical relapse. The trial would be designed to assess the approach (that is, informed testing of MRD) rather than the efficacy of any single drug.
Several issues in the design of such a trial remain. Surrogate (eradication of detectable MRD) and definitive (relapse-free survival) end points will need to be carefully selected to assess for superiority of a rational MRD-targeted treatment approach. Factors such as the frequency of MRD testing, the threshold for therapeutic actionability and issues of standardization and generalizability of implementation will need to be addressed, as will the availability of multiple potentially active therapeutics.
In sum, there is much work to be done, but to quote Theodore Roosevelt
